The cheapest study is not always the least expensive study. A low-cost study that produces unclear or unusable data can become one of the most expensive decisions in a development program.
Better planning protects the budget by making sure the study is designed to answer the right question the first time.
Where study budgets quietly get wasted
Preclinical waste rarely looks dramatic at first. It may show up as an endpoint that does not support the claim, a model that does not reflect the use case, a late test article change, an unclear pathology request, or a final report that leaves reviewers with unanswered questions.
Each issue can create the same result: more meetings, more amendments, more vendor time, more testing, and less confidence in the data.
Planning defines what success looks like
Before selecting a model, vendor, sample size, or endpoint, the team should define the decision the study needs to support. Is the goal to de-risk a design choice, support an IDE, strengthen a 510(k) or De Novo submission, evaluate a material or coating, or prepare for a larger pivotal study?
When the decision is clear, the study can be built around the evidence needed to make that decision.
Endpoints can make or break the value of the study
One of the fastest ways to waste budget is to collect data that cannot be interpreted. Endpoints should be specific, measurable, relevant to the device risk, and practical for the study model. They should also be aligned with how the data will be reported and reviewed.
If the endpoint does not map back to the study objective, it may add cost without adding value.
Model selection affects cost and credibility
A model that is too simple may fail to represent the clinical use case. A model that is more complex than needed may increase cost, timeline, and animal use without improving the decision. Good planning balances biological relevance, regulatory acceptability, operational feasibility, and ethical responsibility.
Readiness reviews prevent avoidable delays
Even strong protocols can stall when practical details are missed. Common delay points include unfinished test articles, incomplete device documentation, limited facility availability, unvalidated methods, missing training, unclear pathology instructions, and late changes to the final device configuration.
A pre-study readiness review can identify these gaps before budget and timelines are locked.
The final report should be planned from the beginning
Teams often focus heavily on execution and underestimate the final report. But the report is the artifact that will be reviewed later. Planning should define how observations, deviations, pathology, imaging, device handling, adverse events, and interpretation will be documented.
The goal is a report that tells a clear data story, not just a record that the study occurred.
Where better planning pays off
Better planning reduces waste because it improves alignment. The study objective, model, endpoints, logistics, quality expectations, and final report should all point to the same development decision.
Need guidance on preclinical strategy, biological evaluation, or study planning? Contact TEM Biomed to discuss your development program.
